Oncology

Drug Development Cancer Treatments Clinical Trials Immunology Drug Sales Immunotherapy Pediatric Oncology Cancer Treatment Trodelvy Targeted Therapies Cancer Drugs Cancer Therapies Precision Medicine Product Sales Aesthetics Targeted Therapy Radiopharmaceuticals Antibody Drug Conjugates RAS Pathway Inhibitors Prostate Cancer Drugs Product Revenue Oncology Supportive Care Hematologic Malignancies Johnson & Johnson Breast Cancer Bladder Cancer

7 ARTICLES

2mo ago

Erasca Faces Securities Suit Over ERAS-0015 After Patent Claim and Trial Death Disclosures

Investors say April disclosures of a Revolution Medicines patent letter and a Phase 1 patient death undercut Erasca’s prior preclinical claims and triggered a fight for lead-plaintiff control.

9 ARTICLES

2mo ago

Johnson & Johnson Beats Q2 Estimates and Lifts Full‑Year Outlook

6 ARTICLES

3mo ago

Erasca Faces Securities Class Actions After April Patent Claim and Patient Death Disclosures

4 ARTICLES

4mo ago

Fennec Q1 Sales Climb 73% to $15.1 Million on PEDMARK Momentum

3 ARTICLES

4mo ago

ADC Therapeutics Reports Higher Q1 Sales and Lower Costs as Zenlonta Readouts Near

9 ARTICLES

5mo ago

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

13 ARTICLES

5mo ago

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

5 ARTICLES

6mo ago

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

4 ARTICLES

8mo ago

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

4 ARTICLES

8mo ago

Aktis Oncology Soars 24% in Nasdaq Debut After $318 Million IPO

3 ARTICLES

8mo ago

AnaptysBio Seeks to Toss Tesaro Anticipatory‑Breach Claim in Jemperli Royalty Dispute

3 ARTICLES

10mo ago

AnaptysBio and GSK’s Tesaro File Dueling Suits Over Jemperli License and Royalties

6 ARTICLES

11mo ago

AbbVie Lifts 2025 Outlook and Dividend After Q3 Revenue Beat as Shares Fall

6 ARTICLES

last yr.

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss

9 ARTICLES

last yr.

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

Oncology

Erasca Faces Securities Suit Over ERAS-0015 After Patent Claim and Trial Death Disclosures

Johnson & Johnson Beats Q2 Estimates and Lifts Full‑Year Outlook

Erasca Faces Securities Class Actions After April Patent Claim and Patient Death Disclosures

Fennec Q1 Sales Climb 73% to $15.1 Million on PEDMARK Momentum

ADC Therapeutics Reports Higher Q1 Sales and Lower Costs as Zenlonta Readouts Near

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Aktis Oncology Soars 24% in Nasdaq Debut After $318 Million IPO

AnaptysBio Seeks to Toss Tesaro Anticipatory‑Breach Claim in Jemperli Royalty Dispute

AnaptysBio and GSK’s Tesaro File Dueling Suits Over Jemperli License and Royalties

AbbVie Lifts 2025 Outlook and Dividend After Q3 Revenue Beat as Shares Fall

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

Never miss stories about

Oncology